Johnson Investment Counsel Inc. Raises Stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Johnson Investment Counsel Inc. boosted its holdings in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 1.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 23,091 shares of the company’s stock after purchasing an additional 382 shares during the period. Johnson Investment Counsel Inc.’s holdings in GE HealthCare Technologies were worth $1,805,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Ashton Thomas Securities LLC purchased a new position in GE HealthCare Technologies during the 3rd quarter worth $26,000. Capital Performance Advisors LLP purchased a new position in GE HealthCare Technologies during the 3rd quarter worth $26,000. Darwin Wealth Management LLC purchased a new position in GE HealthCare Technologies during the 3rd quarter worth $31,000. Continuum Advisory LLC grew its position in GE HealthCare Technologies by 101.8% during the 3rd quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock worth $31,000 after purchasing an additional 168 shares during the last quarter. Finally, Bank of Jackson Hole Trust purchased a new position in GE HealthCare Technologies during the 4th quarter worth $32,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

GE HealthCare Technologies Stock Up 0.3 %

Shares of NASDAQ GEHC opened at $85.59 on Wednesday. The company has a quick ratio of 0.83, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. GE HealthCare Technologies Inc. has a 52 week low of $74.51 and a 52 week high of $94.80. The firm has a 50-day moving average price of $87.06 and a 200 day moving average price of $86.17. The stock has a market capitalization of $39.14 billion, a price-to-earnings ratio of 19.77, a price-to-earnings-growth ratio of 3.19 and a beta of 1.13.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.45 EPS for the quarter, beating the consensus estimate of $1.26 by $0.19. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. The firm had revenue of $5.32 billion during the quarter, compared to analysts’ expectations of $5.33 billion. Equities research analysts anticipate that GE HealthCare Technologies Inc. will post 4.68 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Citigroup raised their target price on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. The Goldman Sachs Group upgraded shares of GE HealthCare Technologies from a “neutral” rating to a “buy” rating and raised their target price for the stock from $85.00 to $100.00 in a research note on Tuesday. Wells Fargo & Company raised their target price on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Finally, Jefferies Financial Group upgraded shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and raised their target price for the stock from $95.00 to $103.00 in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $98.75.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.